NCT05363943 is a NA clinical trial of double plating in Distal Femur Fracture, sponsored by Amr Gamaleldin Mahmoud Khalil Gendya.

Who is sponsoring NCT05363943?

NCT05363943 is sponsored by Amr Gamaleldin Mahmoud Khalil Gendya.

What drugs are being tested in NCT05363943?

Interventions in NCT05363943: double plating, Distal femoral replacement.

What condition does NCT05363943 study?

NCT05363943 studies Distal Femur Fracture, Geriatrics.

Is NCT05363943 still recruiting?

NCT05363943 is currently completed. Last updated 20 July 2023.

Last reviewed 2023-07-20 · How we verify

NCT05363943

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

DP Vs DFR for Management of Geriatric Distal Femur Fractures.

Completed NA Last updated 20 July 2023

What this trial tests

NA trial testing double plating in Distal Femur Fracture in 30 participants. Completed in 31 December 2021.

Timeline

20 August 2018

Primary endpoint
31 December 2021

31 December 2021

Quick facts

Lead sponsor	Amr Gamaleldin Mahmoud Khalil Gendya
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	30
Start date	20 August 2018
Primary completion	31 December 2021
Estimated completion	31 December 2021
Sites	1 location across Egypt

Drugs / interventions tested

double plating
Distal femoral replacement

Conditions studied

Distal Femur Fracture — all drugs for Distal Femur Fracture →
Geriatrics — all drugs for Geriatrics →

Sponsor

Amr Gamaleldin Mahmoud Khalil Gendya

Who can join

60 and older, any sex, with Distal Femur Fracture or Geriatrics. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study was to compare the functional and radiological outcomes of fixation by using double plating technique versus replacement using distal femur tumor prothesis as a primary management for the distal femoral fractures in geriatric patients. The hypothesis was that the distal femoral replacement will yield better functional outcome and earlier rehabilitation and return to pre-injury level of activity.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Distal Femur Fracture

Currently open trials in the same condition.

NCT07280169 — Carbo-fix Lateral Plate Devices and Standard Plate-Nail Constructs in Distal Femur Fractures · NA · recruiting
NCT05805774 — pDIFFIR: Geriatric Periprosthetic DIstal Femur: FIxation Versus Replacement · NA · recruiting
NCT06028971 — Safety and Performance of the Biphasic Plate Distal Femur: A Multicenter Case Series · active not recruiting
NCT05792189 — Distal Femur Fx: ORIF(Open Reduction and Internal Fixation) vs DFR (Distal Femur Replacement Total Knee Arthroplasty) · NA · recruiting
NCT04076735 — DIFFIR - Geriatric Distal Femur Fixation Versus Replacement · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05363943 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Amr Gamaleldin Mahmoud Khalil Gendya
Last refreshed: 20 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05363943.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing